Cargando…
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
BACKGROUND: Though the incidence, characteristics, and pathogenesis of chemotherapy induced peripheral neuropathy (CIPN) by taxane based chemotherapy were extensively studied, diagnostic guidelines extent only recently. AIM: To observationally investigate whether specific tests can be used to predic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575489/ https://www.ncbi.nlm.nih.gov/pubmed/34687287 http://dx.doi.org/10.1002/cnr2.1577 |
_version_ | 1784811326511513600 |
---|---|
author | van Haren, Frank van den Heuvel, Sandra Ligtenberg, Mandy Vissers, Kris Steegers, Monique |
author_facet | van Haren, Frank van den Heuvel, Sandra Ligtenberg, Mandy Vissers, Kris Steegers, Monique |
author_sort | van Haren, Frank |
collection | PubMed |
description | BACKGROUND: Though the incidence, characteristics, and pathogenesis of chemotherapy induced peripheral neuropathy (CIPN) by taxane based chemotherapy were extensively studied, diagnostic guidelines extent only recently. AIM: To observationally investigate whether specific tests can be used to predict and monitor CIPN severity. METHODS: Fourteen female breast cancer patients receiving paclitaxel or docetaxel were evaluated using the McGill Pain Questionnaire (MPQ), National Cancer Institute Common Toxicity Criteria (NCI‐CTC) grading, clinical total neuropathy score (TNSc), quantitative sensory testing (QST) of pressure pain threshold (PPT), and numeric rating scale (NRS) scores and stocking and glove distribution testing (SGDT), at the start (T0), midst (T1), and end (T2) of their treatment and after 3 months (T3). RESULTS: At T3, patients scored NCI‐CTC neuropathy grade 1 (14.3%), 2 (64.3%), and 3 (14.3%) respectively. Fifty percentage scored at least grade 1 at T0, with complaints not caused by CIPN. Pain, if present, was denominated “tingling” and “cold” in the MPQ. Median TNSc score increased from T0 (2.43) to T1 (4.71) to T2 (5.50) to T3 (5.57), as did pinprick and cold sensation disturbances in SGDT. PPT and associated NRS remained unchanged. TNSc and SGDT at T1 could not predict the NCI‐CTC grade at T3. CONCLUSION: NCI‐CTC, TNSc, and stocking and glove distribution testing can be used in the early diagnosis and monitoring of CIPN, with false‐positive findings at baseline. Final NCI‐CTC grades could not be predicted. |
format | Online Article Text |
id | pubmed-9575489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95754892022-10-18 Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes van Haren, Frank van den Heuvel, Sandra Ligtenberg, Mandy Vissers, Kris Steegers, Monique Cancer Rep (Hoboken) Original Articles BACKGROUND: Though the incidence, characteristics, and pathogenesis of chemotherapy induced peripheral neuropathy (CIPN) by taxane based chemotherapy were extensively studied, diagnostic guidelines extent only recently. AIM: To observationally investigate whether specific tests can be used to predict and monitor CIPN severity. METHODS: Fourteen female breast cancer patients receiving paclitaxel or docetaxel were evaluated using the McGill Pain Questionnaire (MPQ), National Cancer Institute Common Toxicity Criteria (NCI‐CTC) grading, clinical total neuropathy score (TNSc), quantitative sensory testing (QST) of pressure pain threshold (PPT), and numeric rating scale (NRS) scores and stocking and glove distribution testing (SGDT), at the start (T0), midst (T1), and end (T2) of their treatment and after 3 months (T3). RESULTS: At T3, patients scored NCI‐CTC neuropathy grade 1 (14.3%), 2 (64.3%), and 3 (14.3%) respectively. Fifty percentage scored at least grade 1 at T0, with complaints not caused by CIPN. Pain, if present, was denominated “tingling” and “cold” in the MPQ. Median TNSc score increased from T0 (2.43) to T1 (4.71) to T2 (5.50) to T3 (5.57), as did pinprick and cold sensation disturbances in SGDT. PPT and associated NRS remained unchanged. TNSc and SGDT at T1 could not predict the NCI‐CTC grade at T3. CONCLUSION: NCI‐CTC, TNSc, and stocking and glove distribution testing can be used in the early diagnosis and monitoring of CIPN, with false‐positive findings at baseline. Final NCI‐CTC grades could not be predicted. John Wiley and Sons Inc. 2021-10-23 /pmc/articles/PMC9575489/ /pubmed/34687287 http://dx.doi.org/10.1002/cnr2.1577 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles van Haren, Frank van den Heuvel, Sandra Ligtenberg, Mandy Vissers, Kris Steegers, Monique Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
title | Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
title_full | Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
title_fullStr | Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
title_full_unstemmed | Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
title_short | Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
title_sort | diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575489/ https://www.ncbi.nlm.nih.gov/pubmed/34687287 http://dx.doi.org/10.1002/cnr2.1577 |
work_keys_str_mv | AT vanharenfrank diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes AT vandenheuvelsandra diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes AT ligtenbergmandy diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes AT visserskris diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes AT steegersmonique diagnostictoolsshouldbeusedforthediagnosisofchemotherapyinducedperipheralneuropathyinbreastcancerpatientsreceivingtaxanes |